Commentary|Articles|October 6, 2026

What HCP Engagement Actually Looks Like For Today’s Digital-First HCPs

Author(s)Vijay Adapala
Listen
0:00 / 0:00

The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.

For years, health care professional (HCP) engagement has rested on a flawed assumption: that more information, delivered across more channels, leads to better clinical decisions. At a time when health care generates nearly a third of the world’s data, that assumption is increasingly hard to sustain.

HCPs aren’t constrained by lack of access; they’re constrained by an inability to act on clinically relevant, patient-personalized insights within the realities of clinical workflows.

HCPs navigate evolving therapies, thousands of active clinical trials and an expanding web of copay and patient support programs often while seeing multiple patients a day. Expecting clinicians to independently retrieve, interpret and apply this volume of information mid-encounter isn’t just inefficient; it’s structurally unsustainable.

The disconnect across systems

New therapies, clinical evidence and affordability programs continue to evolve rapidly, but much of this information remains scattered across fragmented, external systems, forcing clinicians to step outside their workflow to find it. In high-pressure care settings, that friction limits usability. The consequences are measurable: Billions in copay assistance go unused annually, many clinical trials miss enrollment timelines and clinicians frequently remain unaware of relevant therapy updates at the moment decisions are made. These aren’t failures of awareness; they’re failures of delivery.

Engagement must live inside the workflow

The clinical workflow isn’t just a system of record; it’s where care decisions actually happen. Engagement delivered outside it, through disconnected channels or one-off communications, only adds to the fragmentation clinicians are already navigating. What’s needed is a shift from communication to clinical enablement: embedding relevant insights directly into the flow of care, rather than expecting clinicians to seek them out separately.

From overload to precision

Most clinicians already report being overwhelmed by more data than they can reasonably manage. The answer isn’t more information, it’s more precise information: context-aware, patient-personalized and activated in real time, in response to clinical activity rather than imposed on it.

Some health systems are already moving in this direction, piloting models where relevant insights, copay and coverage information and trial-matching surface natively within the electronic health record (EHR) at the moment of decision-making. Early results suggest this reduces cognitive burden while improving access to affordability support and trial opportunities.

Designing engagement without disruption

For engagement to work, it can’t require clinicians to pause, switch systems or change behavior; any friction undermines adoption. The emerging standard is native, in-workflow delivery within the EHR itself, built on a foundation of strong data privacy and compliance with global governance standards.

The path forward

HCP engagement has long been treated as a communication challenge. It’s actually a systems design challenge. Until engagement is built around clinical decision-making, embedded in the workflow, activated by real-time context and tailored to the patient in front of the clinician, it will remain disconnected from care itself.

The future of engagement won’t be defined by how much information reaches HCPs, but by how precisely it supports the decision at hand. In health care, value isn’t created by the availability of information; it’s created by that information’s ability to improve decisions at the point of care.

Vijay Adapala is chief business development officer at Doceree


Related to this article

A Leadership Call to Action for Biotech
Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.
Dr. Bo Liang
CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.